Most whole slide imaging systems are built for high-volume academic labs, which leaves smaller pathology operations choosing between scanners too expensive to justify and workflows still built around glass. Evident’s new Pramana POD benchtop scanner, unveiled at Pathology Visions 2026, targets that gap directly: a compact system rated at 25 slides per hour at true 40X under defined conditions, designed for small and medium-sized labs that cannot absorb the operational overhead of enterprise-class hardware.
The practical bet here is that autonomous image quality beats post-scan correction. The POD’s built-in quality assessment flags scans that need review rather than passing the problem downstream to a pathologist. That matters because post-scan QA is where smaller labs lose time they cannot recover. A pilot with Mayo Clinic on prior Pramana hardware found a 99.5% overall scan acceptability rate, with focus errors flagged algorithmically in 0.4% of slides, suggesting the autonomous QA approach holds up under real clinical volume. The POD extends that same detection architecture to volumetric imaging across multiple focal planes, which handles the tricky specimens, core biopsies and cytology preparations, where a single focal plane misses critical information.
The regulatory posture is worth noting for clinical trial applications specifically. The Pramana line, including the POD, carries a research-use-only designation in the United States, with FDA 510(k) clearance pending. That limits its role in diagnostic or trial-endpoint workflows for now, though labs running translational or exploratory imaging studies can adopt it today. The digital pathology market hit $1.37 billion in 2025 and is growing at an 11.5% annual clip, and much of the unaddressed volume sits in exactly the mid-tier labs Evident is targeting with this system.
The real test for POD’s relevance to clinical trial sites is clearance timing. Sites evaluating digital pathology for protocol-specified tissue analysis need a cleared device, and until that 510(k) lands, the POD functions as infrastructure investment rather than a deployable trial tool. How quickly Evident moves through the regulatory process will determine whether this scanner captures the adoption window or watches it close.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
